TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial.

Lihua E Budde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.